{"id":5186,"date":"2021-11-05T15:00:02","date_gmt":"2021-11-05T12:00:02","guid":{"rendered":"https:\/\/www.klimik.org.tr\/koronavirus\/?p=5186"},"modified":"2021-11-05T15:00:02","modified_gmt":"2021-11-05T12:00:02","slug":"covid-19a-karsi-etkili-ikinci-ilac-yolda-pfizer-agizdan-alinan-covid-ilacinin-hastaneye-yatis-ve-olum-riskini-%89-azalttigini-acikladi","status":"publish","type":"post","link":"https:\/\/www.klimik.org.tr\/koronavirus\/covid-19a-karsi-etkili-ikinci-ilac-yolda-pfizer-agizdan-alinan-covid-ilacinin-hastaneye-yatis-ve-olum-riskini-%89-azalttigini-acikladi\/","title":{"rendered":"COVID-19&#8217;a Kar\u015f\u0131 Etkili \u0130kinci \u0130la\u00e7 Yolda: Pfizer, A\u011f\u0131zdan Al\u0131nan COVID \u0130lac\u0131n\u0131n Hastaneye Yat\u0131\u015f ve \u00d6l\u00fcm Riskini %89 Azaltt\u0131\u011f\u0131n\u0131 A\u00e7\u0131klad\u0131"},"content":{"rendered":"<p><img decoding=\"async\" loading=\"lazy\" class=\"wp-image-107369 alignleft\" src=\"https:\/\/www.klimik.org.tr\/wp-content\/uploads\/2021\/11\/businesswire.png\" alt=\"\" width=\"131\" height=\"32\" \/><strong>Pfizer bug\u00fcn yapt\u0131\u011f\u0131 a\u00e7\u0131klamada, klinik ara\u015ft\u0131rma verilerinin ara analizine g\u00f6re, COVID-19 tedavisi i\u00e7in geli\u015ftirilen oral antiviral ila\u00e7 PAXLOVID\u2122&#8217;in, plaseboya k\u0131yasla hastaneye yat\u0131\u015f ve \u00f6l\u00fcm riskini %89 azaltt\u0131\u011f\u0131n\u0131 duyurdu.<\/strong><\/p>\n<p>PAXLOVID\u2122&#8217;in, COVID-19 ge\u00e7iren hastaneye yat\u0131r\u0131lmam\u0131\u015f y\u00fcksek riskli yeti\u015fkinlerde plaseboya k\u0131yasla hastaneye yat\u0131\u015f veya \u00f6l\u00fcm riskini %89 oran\u0131nda azaltt\u0131\u011f\u0131n\u0131, randomize \u00e7ift k\u00f6r faz 2 \u00e7al\u0131\u015fma sonu\u00e7lar\u0131na dayanarak a\u00e7\u0131klad\u0131.<\/p>\n<p>Genel \u00e7al\u0131\u015fma pop\u00fclasyonunda, plasebo alan hastalarda ger\u00e7ekle\u015fen 10 \u00f6l\u00fcme k\u0131yasla PAXLOVID\u2122 alan hastalarda 28 g\u00fcn boyunca \u00f6l\u00fcm bildirilmedi\u011fi a\u00e7\u0131kland\u0131.<\/p>\n<p>\u015eirket, PAXLOVID\u2122&#8217;in acil kullan\u0131m onay\u0131 ba\u015fvurusunun bir par\u00e7as\u0131 olarak, verileri FDA&#8217;ya sunmay\u0131 planlad\u0131\u011f\u0131n\u0131 a\u00e7\u0131klad\u0131. Ayr\u0131ca, ba\u011f\u0131ms\u0131z bir grup ve FDA ile g\u00f6r\u00fc\u015ft\u00fckten sonra, y\u00fcksek ila\u00e7 etkinli\u011finin saptanmas\u0131 nedeniyle klinik denemelere kay\u0131t almay\u0131 durduraca\u011f\u0131n\u0131 bildirdi.<\/p>\n<p><a href=\"https:\/\/www.businesswire.com\/news\/home\/20211105005260\/en\/Pfizer%E2%80%99s-Novel-COVID-19-Oral-Antiviral-Treatment-Candidate-Reduced-Risk-of-Hospitalization-or-Death-by-89-in-Interim-Analysis-of-Phase-23-EPIC-HR-Study\"><strong>Haber \u0130\u00e7in T\u0131klay\u0131n\u0131z<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer bug\u00fcn yapt\u0131\u011f\u0131 a\u00e7\u0131klamada, klinik ara\u015ft\u0131rma verilerinin ara analizine g\u00f6re, COVID-19 tedavisi i\u00e7in geli\u015ftirilen oral antiviral ila\u00e7 PAXLOVID\u2122&#8217;in, plaseboya k\u0131yasla hastaneye yat\u0131\u015f ve \u00f6l\u00fcm riskini %89 azaltt\u0131\u011f\u0131n\u0131 duyurdu. PAXLOVID\u2122&#8217;in, COVID-19 ge\u00e7iren hastaneye yat\u0131r\u0131lmam\u0131\u015f y\u00fcksek riskli yeti\u015fkinlerde plaseboya k\u0131yasla hastaneye yat\u0131\u015f veya \u00f6l\u00fcm riskini %89 oran\u0131nda azaltt\u0131\u011f\u0131n\u0131, randomize \u00e7ift k\u00f6r faz 2 \u00e7al\u0131\u015fma sonu\u00e7lar\u0131na dayanarak a\u00e7\u0131klad\u0131. Genel \u00e7al\u0131\u015fma pop\u00fclasyonunda, plasebo alan hastalarda ger\u00e7ekle\u015fen 10 \u00f6l\u00fcme k\u0131yasla PAXLOVID\u2122 alan hastalarda 28 g\u00fcn boyunca \u00f6l\u00fcm bildirilmedi\u011fi a\u00e7\u0131kland\u0131. \u015eirket, PAXLOVID\u2122&#8217;in acil kullan\u0131m onay\u0131 ba\u015fvurusunun bir par\u00e7as\u0131 olarak, verileri FDA&#8217;ya sunmay\u0131 planlad\u0131\u011f\u0131n\u0131 a\u00e7\u0131klad\u0131. Ayr\u0131ca, ba\u011f\u0131ms\u0131z bir grup ve FDA ile g\u00f6r\u00fc\u015ft\u00fckten sonra, y\u00fcksek ila\u00e7 etkinli\u011finin [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":5187,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5186"}],"collection":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/comments?post=5186"}],"version-history":[{"count":1,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5186\/revisions"}],"predecessor-version":[{"id":5188,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5186\/revisions\/5188"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media\/5187"}],"wp:attachment":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media?parent=5186"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/categories?post=5186"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/tags?post=5186"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}